Friday's Top 10 Articles, Videos on TheStreet

NEW YORK ( TheStreet) -- In case you missed them, here are the top 10 most popular articles and videos on TheStreet today. Sign up for free email delivery of our daily Top 10.

Biotech Stock Mailbag: Cyclacel Fallout, the Skinny on Vivus, Celldex's Crash
Adam Feuerstein
Biotech columnist Adam Feuerstein answers readers' questions about health-care companies. (Stocks include CYCC, VVUS, CLDX)

The Next Big Thing in Biotech: Discovery Labs
Gregg Greenberg
Senior columnist Adam Feuerstein explains why Discovery Labs is the next big thing in biotech.

The 5 Dumbest Things on Wall Street -- Silent Movie Version
Gregg Greenberg
The show must go on, even if the host loses his voice.

3 Things That Could Move Bank Stocks
Shanthi Bharatwaj
New fees from Bank of America revives debate on whether banks can offset revenue losses by charging customers.

9 Gold, Oil Stocks That Rise on Bad News (Update 1)
Frank Byrt
These companies thrive on political and economic uncertainty -- two things that are certain for the rest of the year.

Investors May Cry For Yelp After IPO (Update 1)
Chris Ciaccia
Reviews site Yelp is going public today. Investors may want to stay away for a variety of reasons.

7 Ex-Dividend Stocks With Buy Ratings
Alexandra Zendrian
These stocks, which go ex-dividend Monday, are rated buy at TheStreet Ratings.

Stocks Waver as Investors Eye Europe
Chao Deng
Stocks waver as European markets weaken and investors watch for developments in Greece's bailout.

Bank Rate Bomb Will Destroy the Smallest and Weakest
Philip van Doorn
The nation's community banks had better be prepared for the possibility of a quick spike in rates of up to 400 basis points within the next few years.

7 Dividend Stocks That Want to Pay You More Cash
Jonas Elmerraji
These companies recently increased their dividend payouts to shareholders.

This article was written by a staff member of TheStreet.

If you liked this article you might like

Biotech Movers: Shire Rises on Encouraging Angioedema Results

Moleculin Biotech gets good verbal Ok from FDA which should cut time to Phase 1/2 trial down

Cyclacel Stock Runs on Momentum Rocket Fueled by 'Dumb & Dumber' Optimism

Here's Why Cyclacel Pharmaceuticals (CYCC) Stock Is Surging Today

Cyclacel Pharmaceuticals (CYCC) Stock Pops, H.C. Wainwright Bullish